An Open Label Multicentric Phase II Study of Panitumumab (Vectibix) in Cutaneous Squamous Cell Carcinoma (SCC).
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Panitumumab (Primary)
- Indications Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PASCE
- 10 Jun 2017 Biomarkers information updated
- 23 Mar 2017 Status changed from recruiting to completed.
- 27 Aug 2010 Actual initiation date (Aug 2010) added as reported by ClinicalTrials.gov.